Ingrid Glimelius' research projects

Hodgkin lymphoma

Below are some examples of our projects on Hodgkin lymphoma, with references to published findings.

High proportions of PD-1 and PD-L1 positive leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome

In this article we illustrate with prognostic impact of the tumour microenvironment in Hodgkin lymphoma.
Paper in Blood Advances

;icroscope image of the tumour microenviroment with tumour cells and inflammatory cells
The tumour microenviroment in Hodgkin lymphoma, with tumour cells and inflammatory cells. The arrow indicates a tumour cell with two nuclei.
Photo: Peter Hollander

Contemporarily treated patients with Hodgkin lymphoma have childbearing potential in line with matched comparators

The childbearing potential in survivors after Hodgkin lymphoma have been investigated together with Caroline Weibull, Karolinska Institutet, and published in Journal of Clinical Oncology. We show that in the absence of relapse, contemporarily treated women have an improved childbearing potential with calendar time and women treated today give birth to the same degree as matched comparators.
Paper in Journal of Clinical Oncology

Pregnancy and the risk of relapse in patients diagnosed with Hodgkin lymphoma

In a related publication in Journal of Clinical Oncology from 2016 we have earlier shown the safety of having children for female survivors, were there was no increased risk of relapse after a pregnancy. 
Paper in Journal of Clinical Oncology

Relapse risk and loss in lifetime after modern combined modality treatment of young patients with Hodgkin lymphoma: A Nordic Lymphoma Epidemiology Group Study

In a recent publication, also in collaboration within the Nordic countries and with Karolinska Institutet, we investigate the overall relapse risk and loss of lifetime years in survivors after Hodgkin lymphoma
Paper in Journal of Clinical Oncology

Mantle Cell Lymphoma

I am national principal investigator in the multinational ENRICH-trial (KFUE Akademiska Sjukhuset): A randomized phase III trial in elderly patients with randomization between Rituximab-Ibrutinib AND Rituximab-chemotherapy (Bendamustine or CHOP) with the aim to test if a chemotherapy free concept can improve survival. In addition, I have been local PI in Uppsala of the Nordic VALERIA trial, testing Lenalidomide-Venetoclax and Rituximab for relapsed/refractory mantle cell lymphoma (MCL) patients. Currently we are including patients in the ALTAMIRA trial testing a minimal residual disease (MRD) driven treatment strategy to try to improve prognosis while also limiting side-effects. With the many novel immunotherapy treatments available patients with lymphoma at Akademiska Sjukhuset are offered CAR-T cell treatments and treatment with bi-specific antibodies.

Register-based studies of outcome for mantel cell lymphoma patients

Together with members of the Swedish Mantle Cell Lymphoma Group and the cancer epidemiology group at Karolinska Institutet, we are involved in several large register-based investigations where we perform real-world studies on the outcome of MCL patients in Sweden. Disease trajectories, outcome, selection to treatment and survivorship issues are investigated.

Comorbidities and causes of death in mantle cell lymphoma

We have recently presented the results of a nationwide population-based cohort study, where we show that the majority of patients dies from the lymphoma, although gender differences exists.
Comorbidities and sex differences in causes of death among mantle cell lymphoma patients – A nationwide population‐based cohort study

Pregnancy and the risk of cancer

In two articles published in International Journal of Cancer, we have presented studies on the association between preterm delivery and risk of epithelial ovarian cancer, and on pregnancy complications and subsequent breast cancer risk in the mother. The collaboration within the Nordic group of perinatal risk factors and cancer has also resulted in a comprehensive review of the field.

Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women

Pregnancy complications and subsequent breast cancer risk in the mother: a Nordic population‐based case–control study

Review: The role of pregnancy, perinatal factors and hormones in maternal cancer risk: a review of the evidence

Last modified: 2023-01-11